Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer-Reference-Cited by-同舟云学术

登录注册会员服务联系我们

Phase II Trial of S-1 as Second-Line Therapy in Patients with Advanced Non-small Cell Lung Cancer

Published:2011-04 Issue:4 Volume:6 Page:790-795
ISSN:1556-0864
Container-title:Journal of Thoracic Oncology
language:en
Short-container-title:Journal of Thoracic Oncology

Author:

Govindan Ramaswamy,Morgensztern Daniel,Kommor Michael D.,Herbst Roy S.,Schaefer Paul,Gandhi Jitendra,Saito Kaku,Zergebel Christopher,Schiller Joan

Publisher

Elsevier BV

Subject

Pulmonary and Respiratory Medicine,Oncology

Reference33 articles.

1. Cancer statistics, 2009;Jemal;CA Cancer J Clin,2009

2. Changing epidemiology of small-cell lung cancer in the United States over the last 30 years: analysis of the surveillance, epidemiologic, and end results database;Govindan;J Clin Oncol,2006

3. Trends in stage distribution for patients with non-small cell lung cancer: a National Cancer Database Survey;Morgensztern;J Thorac Oncol,2010

4. Lung adjuvant cisplatin evaluation: a pooled analysis by the LACE Collaborative Group;Pignon;J Clin Oncol,2008

5. Randomized phase III trial of docetaxel versus vinorelbine or ifosfamide in patients with advanced non-small-cell lung cancer previously treated with platinum-containing chemotherapy regimens. The TAX 320 Non-Small Cell Lung Cancer Study Group;Fossella;J Clin Oncol,2000

Cited by 16 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Efficacy of S‐1 after pemetrexed in patients with non‐small cell lung cancer: A retrospective multi‐institutional analysis;Thoracic Cancer;2021-07-13

2. Oral Chemotherapy for Treatment of Lung Cancer;Frontiers in Oncology;2020-04-28

3. A randomized, phase 2 study of deoxyuridine triphosphatase inhibitor, TAS-114, in combination with S-1 versus S-1 alone in patients with advanced non-small-cell lung cancer;Investigational New Drugs;2020-04-03

4. Neoadjuvant apatinib plus S-1 in locally advanced pulmonary adenocarcinoma;Medicine;2020-01

5. First-in-human phase 1 study of novel dUTPase inhibitor TAS-114 in combination with S-1 in Japanese patients with advanced solid tumors;Investigational New Drugs;2018-12-04

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号京ICP备18003416号-3